This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/925,635	08/09/2001	Nanna Kristensen Soni	4305/1H520US1	2913
7:	590 12/18/2002			
DARBY & DARBY P.C.			EXAMINER	
805 Third Avenue			FOLEY, SHANON A	
New York, NY	10022			
			ART UNIT	PAPER NUMBER
			1648	•
			DATE MAILED: 12/18/2002	7

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)				
	09/925,635	SONI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Shanon Foley	1648				
Th MAILING DATE of this communication appeared for Reply	pears on the cover s	she t with the correspondence	address			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however ly within the statutory minim will apply and will expire SI e, cause the application to b	er, may a reply be timely filed num of thirty (30) days will be considered tin X (6) MONTHS from the mailing date of this secome ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>09</u>	<u>August 2001</u> .					
2a) ☐ This action is FINAL . 2b) ☑ The	nis action is non-fin	al.				
Since this application is in condition for allow closed in accordance with the practice under Disposition of Claims			the merits is			
4) Claim(s) 1-47 and 51-64 is/are pending in the	e application.					
4a) Of the above claim(s) is/are withdra	wn from considerat	ion.				
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-47 and 51-64</u> are subject to restrict	tion and/or election	requirement.				
Application Papers						
9) The specification is objected to by the Examine						
10) The drawing(s) filed on is/are: a) □ acce		-	- >			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120	Carrintor.					
13) Acknowledgment is made of a claim for foreig	n priority under 35	LS C. & 119(a)-(d) or (f)				
a) ☐ All b) ☐ Some * c) ☐ None of:	in priority under 00	5.5.5. g 175(a) (a) 61 (i).				
1.☐ Certified copies of the priority document	ts have been receiv	red				
2. Certified copies of the priority document						
			al Stage			
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domest	ic priority under 35	U.S.C. § 119(e) (to a provision	nal application).			
 a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domest 						
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 1	nterview Summary (PTO-413) Paper Notice of Informal Patent Application (Other:				

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-20, 58, 59, drawn to a parenteral vaccine comprising an immunogen and an adjuvant, classified in class 424, subclass 184.1.
- II. Claims 21-47, drawn to an adjuvant composition, classified in class 424, subclass278.1.
- III. Claims 51-57 and 60-64, drawn to a method of preparing a parenteral vaccine, classified in class 435, subclass 173.9.

If applicant elects groups I, II or III, applicant must also elect a single salt from group 2 of the Periodic Table: Mg, Ca, Sr, Ba, Ra

or,

a single salt from group 4 of the Periodic Table: Ti, Zr, Hf, Rf.

If applicant elects groups I, II or III and has elected the required single salt, applicant must also elect a single conjugate to complete the adjuvant salt complex from the following list (which is also listed in claim 4 for example):

- A) Oxides
- B) Peroxides
- C) Hydroxides
- D) Carbonates
- E) Phosphates
- F) Pyrophosphates

Application/Control Number: 09/925,635

Art Unit: 1648

G) Hydrogenphosphates

H) Dihydrogenphosphates

I) Sulphates

J) Silicates

K) Hydrates

Alternatively, if applicant elects groups I, II or III, applicant may also elect a single, specific combination comprising one salt from groups 2 or 4 and several conjugates A-K; examples of this single combination is found in claim 17

Also, if applicant elects groups I, II or III and desires to elect a combination of different salt compounds as the adjuvant, as required in claim 19 for example, applicant must specifically elect no more than three specific salt complexes.

The inventions are distinct, each from the other because of the following reasons:

Each of the elements in groups 2 and 4 of the Periodic Table and each of the complexes listed in groups A-K are distinct. Each of the elements and A-K comprise distinct molecular characteristics, properties and masses. These distinct physical properties are the basis for different functional characteristics that differentiate each element and complex. See MPEP § 806.04 and MPEP § 808.01.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the vaccine composition of group I comprises ingredients that are not included in the adjuvant composition of group II. Also, the vaccine composition may be used to treat or prevent

Application/Control Number: 09/925,635

Art Unit: 1648

a specific infection caused by a pathogenic agent, while the adjuvant composition is used to nonspecifically boost an immune response.

Inventions I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the method can be used to prepare a number of different vaccines comprising distinct adjuvants and immunogens from various pathogens.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shanon Foley whose telephone number is (703) 308-3983. The examiner can normally be reached on M-F 9:00-5:30.

Page 5

Application/Control Number: 09/925,635

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (703) 308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4426 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Shanon Fo

December 14, 2002

JAMES HOUSEL

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600